ARWR Arrowhead Pharmaceuticals (ARWR) Q3 FY26 earnings call
Arrowhead Pharmaceuticals reported strong Q3 FY26 results, highlighted by positive Phase III SHASTA data for plozasiran in severe hypertriglyceridemia (sHTG), demonstrating significant triglyceride reduction and acute pancreatitis event reduction. The company acquired a Priority Review Voucher to accelerate regulatory review for sHTG, aiming for a faster market entry. REDEMPLO's FCS launch continues to build momentum, and the broader cardiometabolic pipeline, including ARO-INHBE and ARO-DIMER-PA, shows promising progress, positioning Arrowhead for substantial future growth and market expansion
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
Inve summary of the company's earnings call; see how call summaries are prepared. Not investment advice.